These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23535021)

  • 1. Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes.
    Ishii M; Kojima N
    Int Immunopharmacol; 2013 Apr; 15(4):685-92. PubMed ID: 23535021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of invariant natural killer T cells by α-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice.
    Homma T; Kinugawa S; Takahashi M; Sobirin MA; Saito A; Fukushima A; Suga T; Takada S; Kadoguchi T; Masaki Y; Furihata T; Taniguchi M; Nakayama T; Ishimori N; Iwabuchi K; Tsutsui H
    J Mol Cell Cardiol; 2013 Sep; 62():179-88. PubMed ID: 23774048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation.
    Iyoda T; Ushida M; Kimura Y; Minamino K; Hayuka A; Yokohata S; Ehara H; Inaba K
    Int Immunol; 2010 Nov; 22(11):905-13. PubMed ID: 21118907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro analyses of α-galactosylceramide uptake by conventional dendritic cell subsets using its fluorescence-labeled derivative.
    Ushida M; Iyoda T; Kanamori M; Watarai H; Takahara K; Inaba K
    Immunol Lett; 2015 Dec; 168(2):300-5. PubMed ID: 26481266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
    Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
    Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting with oligomannose-coated liposomes promotes maturation and splenic trafficking of dendritic cells in the peritoneal cavity.
    Ishii M; Kato C; Hakamata A; Kojima N
    Int Immunopharmacol; 2011 Feb; 11(2):164-71. PubMed ID: 21112331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
    Nakamura T; Yamazaki D; Yamauchi J; Harashima H
    J Control Release; 2013 Oct; 171(2):216-24. PubMed ID: 23860186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
    Macho Fernandez E; Chang J; Fontaine J; Bialecki E; Rodriguez F; Werkmeister E; Krieger V; Ehret C; Heurtault B; Fournel S; Frisch B; Betbeder D; Faveeuw C; Trottein F
    Int J Pharm; 2012 Feb; 423(1):45-54. PubMed ID: 21575695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
    Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
    J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
    Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
    Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano spray dryer for vectorizing α-galactosylceramide in polymeric nanoparticles: A single step process to enhance invariant Natural Killer T lymphocyte responses.
    Gonzatti MB; Sousa MEP; Tunissi AS; Mortara RA; de Oliveira AM; Pereira Cerize NN; Keller AC
    Int J Pharm; 2019 Jun; 565():123-132. PubMed ID: 31075434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of peritoneal macrophage along a dendritic cell lineage in response to uptake of oligomannose-coated liposomes.
    Kojima N; Kato C; Igarashi M; Ishii M
    Cell Immunol; 2011; 271(2):335-41. PubMed ID: 21875704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Inverse Correlation in the Activation of Natural Killer T Cells Through Dual-Signal Stimulation via a Combination of α-Galactosylceramide-Loaded Liposomes and Interleukin-12.
    Abdelmegeed H; Nakamura T; Harashima H
    J Pharm Sci; 2016 Jan; 105(1):250-6. PubMed ID: 26852856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
    Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
    J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of marginal zone B lymphocytes in invariant NKT cell activation.
    Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
    J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galacto-configured aminocyclitol phytoceramides are potent in vivo invariant natural killer T cell stimulators.
    Harrak Y; Barra CM; Delgado A; Castaño AR; Llebaria A
    J Am Chem Soc; 2011 Aug; 133(31):12079-84. PubMed ID: 21728320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide.
    Ivanov S; Fontaine J; Paget C; Macho Fernandez E; Van Maele L; Renneson J; Maillet I; Wolf NM; Rial A; Léger H; Ryffel B; Frisch B; Chabalgoity JA; Sirard JC; Benecke A; Faveeuw C; Trottein F
    J Infect Dis; 2012 Sep; 206(5):723-34. PubMed ID: 22723642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.